Acute coronary syndrome: What is the cost-effectiveness of prevention, point-of-care technology and telemonitoring?

被引：6

作者：

Van Dyck, Walter ^{[1
]}

Vertes, Gergely ^{[1
]}

Palaniappan, Muhilan ^{[1
]}

Gassull, Daniel ^{[1
]}

Jain, Prateek ^{[1
]}

Schulthess, Duane ^{[2
]}

Tambuyzer, Erik ^{[2
]}

Hudson, Richard ^{[2
]}

Moran, Nuala ^{[2
]}

机构：

[1] Vlerick Leuven Gent Management Sch, B-9000 Ghent, Belgium

[2] Sci Business, B-1040 Brussels, Belgium

来源：

HEALTH POLICY AND TECHNOLOGY | 2012年 / 1卷 / 03期

关键词：

D O I：

10.1016/j.hlpt.2012.07.002

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

This study is a cost-analysis that calculates the impact of three interventions for patients identified as 'at risk' for Acute Coronary Syndrome - a cardio-vascular exercise programme, point-of-care digital diagnostics, and telemonitoring adherence tools. The methodology utilizes a model of the annualized costs of ACS for the entire treatment value chain, and measures the impact of the three interventions by the change in treatment cost, incremental net benefit, and QALY. The results demonstrate that the largest impact is measured when all three interventions are utilized simultaneously producing a cumulative savings of 4424 and 0.126 QALY per patient. We also find a significant decrease in Emergency Room visits by 15% and changes in rates of utilization of Catharization (-59%), Angioplasty (-59%), Bypass (-17%), Medication (-14%) and Rehabilitation (-13%). (C) 2012 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. All rights reserved.

引用

页码：173 / 177

页数：5

共 50 条

[21] THE COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR (CV) EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) IN TURKEY
Parali, E.
Deger, C.
Ozdemir, O.
Afsar, N.
Aykut Aka, S.
Degertekin, M.
Ergene, O.
Ongen, Z.
Ozdemir, M.
Sumer, F.
Yilmaz, Z. S.
Ozel, M. O.
VALUE IN HEALTH, 2014, 17 (03) : A115 - A115
[22] COST-EFFECTIVENESS OF GENOTYPE-DRIVEN ANTIPLATELET THERAPY FOR SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME
Crespin, D. J.
Federspiel, J. J.
Biddle, A. K.
Jonas, D.
Stearns, S. C.
Rossi, J. S.
VALUE IN HEALTH, 2010, 13 (03) : A162 - A162
[23] Cost-effectiveness of prevention of coronary disease in Germany
Lauterbach, KW
Gerber, A
Klever-Deichert, G
Stollenwerk, B
ZEITSCHRIFT FUR KARDIOLOGIE, 2005, 94 : 100 - 104
[24] A COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME IN GREECE
Kritikou, P.
Yfantopoulos, J.
VALUE IN HEALTH, 2011, 14 (07) : A379 - A379
[25] COST-EFFECTIVENESS OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH RIVAROXBAN IN AUSTRALIA
Gao, L.
Li, S. C.
VALUE IN HEALTH, 2014, 17 (07) : A760 - A760
[26] COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME (ACS) PATIENTS IN SPAIN
Thurston, S.
Webb, C.
Rejas, J.
Van Hout, B.
VALUE IN HEALTH, 2010, 13 (03) : A165 - A166
[27] Point-of-care ultrasound in acute coronary syndrome–it’s about time
Bruce J. Kimura
Keshav R. Nayak
Internal and Emergency Medicine, 2023, 18 : 15 - 17
[28] Cost-effectiveness of Autonomous Point-of-Care Diabetic Retinopathy Screening for Pediatric Patients With Diabetes
Wolf, Risa M.
Channa, Roomasa
Abramoff, Michael D.
Lehmann, Harold P.
JAMA OPHTHALMOLOGY, 2020, 138 (10) : 1063 - 1069
[29] Cost-effectiveness and laboratory turnaround time using expanded point-of-care testing in the ICU
Giuliano, KK
Higgins, TL
Pysznik, E
McGee, W
Perkins, S
Jaciow, D
CRITICAL CARE MEDICINE, 1999, 27 (01) : A115 - A115
[30] THE COST-EFFECTIVENESS OF ANTENATAL SYPHILIS SCREENING USING POINT-OF-CARE TESTING IN LATIN AMERICA
Komakech, H.
Muhumuza, C.
Lamorde, M.
Marques, E.
Kuznik, A.
VALUE IN HEALTH, 2014, 17 (03) : A160 - A160

← 1 2 3 4 5 →